Aliases & Classifications for Rheumatic Disease

MalaCards integrated aliases for Rheumatic Disease:

Name: Rheumatic Disease 12 15 17
Rheumatic Diseases 54
Collagen Diseases 71
Rheumatism 71

Classifications:



External Ids:

Disease Ontology 12 DOID:1575
ICD10 32 M79.0
UMLS 71 C0009326 C0035435

Summaries for Rheumatic Disease

Disease Ontology : 12 An autoimmune hypersensitivity disease that involves inflammation or pain in the muscles, joints, or fibrous tissue.

MalaCards based summary : Rheumatic Disease, also known as rheumatic diseases, is related to spondyloarthropathy 1 and juvenile rheumatoid arthritis, and has symptoms including myalgia, joint symptom and musculoskeletal symptom. An important gene associated with Rheumatic Disease is TNF (Tumor Necrosis Factor), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Acetaminophen and Hydrocortisone acetate have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and bone, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : 74 Rheumatism or rheumatic disorders are conditions causing chronic, often intermittent pain affecting the... more...

Related Diseases for Rheumatic Disease

Diseases related to Rheumatic Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1034)
# Related Disease Score Top Affiliating Genes
1 spondyloarthropathy 1 33.7 TNFRSF11B TNF IL1R1 HLA-B CRP CD40LG
2 juvenile rheumatoid arthritis 33.3 TNF IL2RA IL1R1 IL1B IL10 IFNG
3 systemic scleroderma 33.3 TRIM21 TNF SSB IFNG CRP CD40LG
4 palindromic rheumatism 33.3 TNF PADI4 IL1B HLA-DRB1
5 spondylitis 32.5 TNF IL10 IFNG HLA-B CRP
6 rheumatoid arthritis 32.3 TNFRSF11B TNF PTGS2 PTGS1 PADI4 IL2RA
7 fibromyalgia 32.2 TNF IL1B IL10 CRP
8 vasculitis 32.2 TNF HLA-B CRP CD40LG APOH
9 psoriatic arthritis 32.0 TNFRSF11B TNF IL1B IL10 IFNG HLA-DRB1
10 osteoarthritis 31.9 TNFRSF11B TNF PTGS2 PTGS1 IL1R1 IL1B
11 arthropathy 31.9 TNFRSF11B TNF PTGS2 IL1B IFNG HLA-B
12 spondyloarthropathy 31.9 TNF IL1B IL10 IFNG HLA-B
13 synovitis 31.9 TNFRSF11B TNF IL1B HMGB1 CRP
14 connective tissue disease 31.8 TNFRSF11B TNF SSB RNPC3 IL1B IL10
15 myositis 31.8 TRIM21 TNF IL1B IFNG HLA-DRB1 HLA-B
16 rheumatic fever 31.8 TNF IL10 IFNG HLA-DRB1 CD40LG
17 uveitis 31.8 TNF IL2RA IL1R1 IL10 IFNG HLA-B
18 childhood type dermatomyositis 31.8 TRIM21 TNF CD40LG
19 reactive arthritis 31.8 TNF IL1B IL10 IFNG HLA-B CRP
20 mixed connective tissue disease 31.8 TNF RNPC3 IL10 IFNG HLA-DRB1 CD40LG
21 antiphospholipid syndrome 31.7 TNF CRP CD40LG APOH
22 temporal arteritis 31.7 TNF IFNG HLA-DRB1 CRP CD40LG APOH
23 autoimmune disease 31.6 TRIM21 TNF PADI4 IL2RA IL1R1 IL1B
24 systemic onset juvenile idiopathic arthritis 31.6 TNF IL1B
25 familial mediterranean fever 31.6 TNF IL1R1 IL1B IL10 CRP
26 iridocyclitis 31.6 TNF HLA-B CRP CD40LG
27 sjogren syndrome 31.5 TRIM21 SSB IL2RA IL10 CD40LG APOH
28 relapsing polychondritis 31.5 IL10 IFNG CRP
29 polyarteritis nodosa 31.5 HLA-DRB1 CRP APOH
30 lung disease 31.5 TNF IL1B IL10 IFNG HMGB1 CRP
31 granulomatosis with polyangiitis 31.5 TNF HMGB1 CRP CD40LG
32 scleritis 31.4 TNF IFNG CRP
33 sarcoidosis 1 31.4 TNF IL2RA IL1B IFNG HLA-DRB1 CRP
34 adult-onset still's disease 31.4 TNF IL1R1 IL1B HLA-DRB1 CRP
35 rheumatic heart disease 31.4 TNF IL1B IL10 HLA-DRB1
36 interstitial lung disease 31.4 TRIM21 TNF IL1B IL10 IFNG CRP
37 bursitis 31.4 TNF PTGS2 CRP
38 osteoporosis 31.4 TNFRSF11B TNF PTGS2 IL2RA IL1B IL11
39 arthritis 31.4 TNF PTGS2 PTGS1 PADI4 IL1R1 IL1B
40 peptic ulcer disease 31.4 TNF PTGS2 PTGS1 IL1B IL10
41 purpura 31.3 TNF IL10 CRP CD40LG APOH
42 exanthem 31.3 TRIM21 TNF IL10 CRP CD40LG
43 systemic lupus erythematosus 31.3 TRIM21 TNF SSB RNPC3 PADI4 IL2RA
44 bone resorption disease 31.3 TNFRSF11B TNF CRP
45 kawasaki disease 31.3 TNF IL1B IL10 CRP CD40LG
46 chickenpox 31.3 TNF IL10 IFNG CRP CD40LG
47 gastritis 31.2 TNF PTGS2 PTGS1 IL1B IL10
48 myocarditis 31.2 TNF IL1B IL10 IFNG HLA-B CD40LG
49 tenosynovitis 31.2 TNF CRP CD40LG
50 collagen disease 31.2 TRIM21 TNF SSB IL10 CRP CD40LG

Graphical network of the top 20 diseases related to Rheumatic Disease:



Diseases related to Rheumatic Disease

Symptoms & Phenotypes for Rheumatic Disease

UMLS symptoms related to Rheumatic Disease:


myalgia, joint symptom, musculoskeletal symptom

GenomeRNAi Phenotypes related to Rheumatic Disease according to GeneCards Suite gene sharing:

26 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 10.02 IL2RA
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-109 10.02 HMGB1
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-130 10.02 IL2RA
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 10.02 IL2RA
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-141 10.02 APOH
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 10.02 HMGB1 SSB
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 10.02 APOH HMGB1 IL10 IL2RA SSB
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 10.02 HMGB1 IL2RA
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 10.02 IL2RA
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 10.02 SSB
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 10.02 IL10 IL2RA
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.02 IL10
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 10.02 APOH
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 10.02 IL10 SSB
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 10.02 IL10
16 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.83 APOH CD40LG IL10 IL1B IL2RA SSB
17 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.83 APOH CD40LG IL10 IL1B IL2RA SSB

MGI Mouse Phenotypes related to Rheumatic Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.21 CD40LG IFNG IL10 IL1B IL1R1 IL2RA
2 immune system MP:0005387 10.2 CD40LG CRP IFNG IL10 IL1B IL1R1
3 cardiovascular system MP:0005385 10.14 CD40LG CRP IFNG IL10 IL1B IL1R1
4 mortality/aging MP:0010768 10.03 APOH CD40LG IFNG IL10 IL1B IL1R1
5 integument MP:0010771 9.96 CD40LG IFNG IL10 IL1B IL1R1 PTGS1
6 neoplasm MP:0002006 9.5 IFNG IL10 IL1B IL1R1 PTGS1 PTGS2
7 skeleton MP:0005390 9.32 CD40LG IFNG IL10 IL1B IL1R1 IL2RA

Drugs & Therapeutics for Rheumatic Disease

Drugs for Rheumatic Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 393)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetaminophen Approved Phase 4 103-90-2 1983
2
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
3
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
4
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
5
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
6
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
7
Tranexamic Acid Approved Phase 4 1197-18-8 5526
8
Aminocaproic acid Approved, Investigational Phase 4 60-32-2 564
9
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
10
Aceclofenac Approved, Investigational Phase 4 89796-99-6
11
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
12
Tofacitinib Approved, Investigational Phase 4 477600-75-2
13
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
14
Dalteparin Approved Phase 4 9005-49-6
15
Betrixaban Approved, Investigational Phase 4 330942-05-7
16
Abatacept Approved Phase 4 332348-12-6 10237
17
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
18
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
19 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
20
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
21
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
22
Leflunomide Approved, Investigational Phase 4 75706-12-6 3899
23
Denosumab Approved Phase 4 615258-40-7
24
Nimodipine Approved, Investigational Phase 4 66085-59-4 4497
25
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
26
leucovorin Approved Phase 4 58-05-9 6006 143
27
Adalimumab Approved Phase 4 331731-18-1 16219006
28
Etanercept Approved, Investigational Phase 4 185243-69-0
29
Infliximab Approved Phase 4 170277-31-3
30
Ribavirin Approved Phase 4 36791-04-5 37542
31
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
32
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
33
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
34
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
35 Cyclooxygenase 2 Inhibitors Phase 4
36 Hypolipidemic Agents Phase 4
37 Anticholesteremic Agents Phase 4
38 Lipid Regulating Agents Phase 4
39 Gentamicins Phase 4
40 Hydrocortisone hemisuccinate Phase 4
41 Hydrocortisone-17-butyrate Phase 4
42 Hydrocortisone 17-butyrate 21-propionate Phase 4
43 Antineoplastic Agents, Immunological Phase 4
44 Cholestyramine Resin Phase 4
45 Estrogens Phase 4
46 Estrogens, Conjugated (USP) Phase 4
47 Antirheumatic Agents Phase 4
48 Vaccines Phase 4
49 Antithrombins Phase 4
50 HIV Protease Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 546)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
2 The Efficacy and Safety of Vaccination Against Pertussis. Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
3 A Randomized, Double Blind, Single Simulation, Parallel Controlled, Multi-center Clinical Study of Guli Capsules in the Treatment of Knee Osteoarthritis Unknown status NCT02484508 Phase 4 Guli capsule;Kangguzengsheng capsule
4 The Efficacy of Adalimumab and Conventional Antirheumatic Drugs in Alleviating Axial and Aortic Inflammation Detected in PET/CT in Patients With Axial Spondyloarthritis Unknown status NCT02634541 Phase 4 Adalimumab
5 Targeting Synovitis in Early Rheumatoid Arthritis (TaSER). Intensive Management of Early Rheumatoid Arthritis Using Either Clinical or Musculoskeletal Ultrasound Assessment of Synovitis − a Randomised Study With Blinded Outcome Assessments Unknown status NCT00920478 Phase 4
6 Prospective Cohort Study of the Influence of Age, Underlying Disease and Immunosuppression on Vaccine Responses to Influenza A H1N1/09 Immunization in High-risk Patients. Completed NCT01022905 Phase 4
7 A Prospective, Randomised, Uncontrolled, Single-Centre, Post-Market Surveillance Study To Evaluate The Performance Of SmartSet® HV and SmartSet® GHV Bone Cements In Primary Cemented Total Hip Arthroplasty(THA) Completed NCT00872066 Phase 4
8 Patient Self-administration of Cortisol for Cortisol-responding Disorders in Men and Women Over the Age of 17, Demonstration of Double-blind Trial Results Completed NCT03558971 Phase 4 Cortisol
9 A Prospective, Randomised, Controlled, Single Centre, Blinded Study of the Wear Characteristics of Two Polyethylene Bearing Surfaces, Enduron vs. Marathon Completed NCT00208442 Phase 4
10 Spa Therapy in Knee Osteoarthritis: Study on Cost/Effectiveness - Cost/Utility and Possible Mechanisms of Action Completed NCT01538043 Phase 4
11 Acetaminophen for Mood and Memory Changes Associated With Prednisone Therapy Completed NCT00377364 Phase 4 Drug: Acetaminophen, Drug: Placebo
12 Immunogenicity and Safety of a Herpes Zoster Vaccine (Zostavax) in Patients With Systemic Lupus Erythematosus: a Randomized Controlled Trial Completed NCT02477150 Phase 4
13 A Randomized Controlled Trial of Tranexamic Acid and ε-Aminocaproic Acid to Reduce Blood Loss Following Total Knee Arthroplasty Completed NCT01873768 Phase 4 Tranexamic Acid (TXA);ε-Aminocaproic Acid (EACA)
14 Immunogenicity and Safety of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases Completed NCT03540823 Phase 4
15 Low Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid Arthritis Completed NCT01593332 Phase 4 Rituximab;Rituximab
16 Phase IV STudy of Tacrobell in Active Rheumatoid Arthritis Completed NCT01746680 Phase 4 Tacrolimus with Methotrexate
17 Evaluating the Addition of Obturator Nerve Block to Adductor Canal Block for Total Knee Arthroplasty Completed NCT03326999 Phase 4 Obturator nerve regional block;Adductor canal regional block;Saline
18 Comparison of Lower Dosage of Etoricoxib Versus Aceclofenac in the Treatment of Patients With Rheumatoid Arthritis: A Single-center, Parallel-group, Randomized Controlled Pilot Study Completed NCT04144101 Phase 4 Etoricoxib;Aceclofenac
19 Open-Label Study To Evaluate The EULAR-RAID Score, Rheumatoid Arthritis Impact Of Disease Score, In Rheumatoid Arthritis Patients Eligible To Etanercept And Who Will Receive Etanercept Completed NCT00768053 Phase 4 Etanercept
20 Effects of Atorvastatin on Disease Activity and HDL Cholesterol Anti-inflammatory Properties in Patients With Rheumatoid Arthritis Completed NCT00356473 Phase 4 Atorvastatin
21 Predictors of the Response to Adalimumab in Rheumatoid Arthritis Completed NCT00234234 Phase 4 Adalimumab
22 A Phase 4, Multicenter, Open-Label, Assessor-Blinded Switch Study of the Efficacy and Safety of Infliximab (REMICADE) in Patients With Active Rheumatoid Arthritis Who Are Responding Inadequately to Etanercept (ENBREL) or Adalimumab (HUMIRA). Completed NCT00714493 Phase 4
23 Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response By Switching to Certolizumab Pegol (Cimzia)? A Phase IV, Randomized, Multi-Center, Double-Blind, Twelve-Week Study Followed by a 12-Week Open-Label Phase Completed NCT01147341 Phase 4 Cimzia;Placebo
24 Effects of NSAIDs on RAdiographic Damage in Ankylosing Spondylitis (ENRADAS) - a Prospective Randomised Controlled Trial Completed NCT00715091 Phase 4 diclophenac;diclophenac
25 Short and Long-term Immunogenicity and Safety Following the 23-valent Polysaccharide Pneumococcal Vaccine in Juvenile Idiopathic Arthritis Patients Under Anti-TNF Therapy Completed NCT02196480 Phase 4
26 Improvement in Pain, Function and Quality of Life With a Protocolized Exercise Program Compared With Non-steroidal Anti-inflammatory Analgesics in Patients With Subacute Low Back Pain in Medellín, Colombia, 2009-2010 Completed NCT01374269 Phase 4 NSAID (Nonsteroidal anti-inflammatory drugs)
27 Effect Of Hormone Replacement Therapy On Disease Activity, Menopausal Symptoms And Bone Mineral Density In Peri/Postmenopausal Women With Systemic Lupus Erythematosus.Randomized Clinical Trial Completed NCT00392093 Phase 4 Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
28 MIRACLE (Methotrexate Inadequate Response Patient With Rheumatoid Arthritis Treated by Adalimumab in Combination With Low-dose Methotrexate) Study Recruiting NCT03505008 Phase 4 Methotrexate;Adalimumab
29 Effect of Hydroxychloroquine on Endothelial Function: a Clinical Trial Recruiting NCT04161339 Phase 4 Hydroxychloroquine;Placebo oral tablet
30 Randomized Controlled Trial of Computerized Decision Support for Prevention of Venous Thromboembolism in Hospitalized Medical Patients Across the Continuum of Care (DC-eALERT) Recruiting NCT03728166 Phase 4
31 Adalimumab Drug Optimisation in Rheumatoid Arthritis Using Therapeutic Drug Monitoring (ADDORA): Multi-centre Open Label Randomised Controlled Trail Recruiting NCT04194827 Phase 4 Adalimumab
32 Safety and Tolerability of Herpes Zoster Vaccine in Patients With Rheumatoid Arthritis Immunized Prior to Biologics and Tofacitinib Therapy Initiation Recruiting NCT03016884 Phase 4
33 Abatacept Versus Tocilizumab by Subcutaneous Administration for the Treatment of Rheumatoid Arthritis in TNF Alpha Inhibitor Inadequate Responder Patients: A Randomized, Open-labeled, Superiority Trial Recruiting NCT03227419 Phase 4 Tocilizumab Prefilled Syringe;Abatacept Prefilled Syringe
34 Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease. Impact of Antirheumatic Treatment on Antibody Response. Active, not recruiting NCT03762824 Phase 4
35 The Glucocorticoid Low-dose Outcome in RheumatoId Arthritis Study Comparing the Cost-effectiveness and Safety of Additional Low-dose Glucocorticoid in Treatment Strategies for Elderly Patients With Rheumatoid Arthritis Active, not recruiting NCT02585258 Phase 4 Prednisolone
36 EFFECTS OF ABATACEPT ON THE PROGRESSION TO RHEUMATOID ARTHRITIS IN PATIENTS WITH PALINDROMIC RHEUMATISM (PALABA) Not yet recruiting NCT03669367 Phase 4 Abatacept Injection;hydroxycloroquina
37 Abatacept to Silence Anti-citrullinated Protein Antibody-expressing B Cells in Rheumatoid Arthritis (ASCARA). Not yet recruiting NCT03492658 Phase 4 Abatacept;Methotrexate
38 A Randomized, Controlled Trial to Evaluate Leflunomide Plus Low Dose Corticosteroid Therapy in Progressive IgA Nephropathy With Renal Insufficiency Not yet recruiting NCT04020328 Phase 4 Leflunomide 20 mg+prednisone 0.5mg/kg/d
39 Romosozumab Versus Denosumab for Osteoporosis in Long-term Glucocorticoid Users: an Open Randomized Controlled Trial Not yet recruiting NCT04091243 Phase 4 Romosozumab
40 Comparison of the Efficacy of Corticosteroid Injection and Extracorporeal Shock Wave Therapy (ESWT) in Patients With Carpal Tunnel Syndrome; A Prospective Randomized Controlled Trial Not yet recruiting NCT03792945 Phase 4 local injection
41 Prospective, Uncontrolled, Multi-Centre, Post-Marketing Surveillance Study to Evaluate the Long-Term Performance of Summit Tapered Hip in Cementless Total Hip Arthroplasty Terminated NCT00208390 Phase 4
42 Prospective, Uncontrolled, Two-centre, RSA, Post-market Surveillance Study to Evaluate the Stability of the C-Stem™ AMT Femoral Component in Primary Total Hip Arthroplasty. Terminated NCT00872573 Phase 4
43 Uncontrolled Prospective Multi-Centre Post Marketing Surveillance Study to Monitor the Long Term Survivorship of Pinnacle™ Acetabular Cup Prosthesis With a Ceramic-on-ceramic Bearing in Subjects With Aetiologies Requiring a Primary Total Hip Replacement Terminated NCT00872222 Phase 4
44 Prospective Multi-Centre, Uncontrolled, Post Marketing Surveillance Study to Monitor the Long-Term Performance of the DePuy ASR Hip System in Subjects With Suitable Indications for a Primary Resurfacing Hip Arthroplasty Terminated NCT00208377 Phase 4
45 Uncontrolled Prospective Multi-Centre Post Marketing Surveillance Study to Monitor the Long Term Survivorship of Pinnacle Acetabular Cup Prosthesis With a Metal on Metal Bearing in Subjects With Aetiologies Requiring a Primary Total Hip Replacement Terminated NCT00208364 Phase 4
46 Randomised, Controlled, Prospective, Multi-Centre, Post Market Surveillance Study Comparing a Ceramic-on-Metal Bearing and a Metal-on-Metal Bearing in Subjects Requiring Primary Total Hip Arthroplasty for Non-Inflammatory Degenerative Joint Disease Terminated NCT00873444 Phase 4
47 Prospective Single-centre, Uncontrolled, Post Marketing Surveillance Study to Monitor the Long-term Performance of the DePuy ASR™ Hip in Subjects With Suitable Indications for a Primary Resurfacing Hip Arthroplasty Terminated NCT00872794 Phase 4
48 Prospective, International Multi-centre, Uncontrolled, Post Marketing Surveillance Study to Monitor the Long-term Performance of a Large Metal-on-Metal (MoM) Bearing Comprising a DePuy ASR™ Cup in Conjunction With Either a DePuy ASR™ Hip Resurfacing Femoral Component or a DePuy ASR™ XL Head in Subjects With Indications Suitable for Either a Primary Resurfacing Arthroplasty or Primary Total Hip Arthroplasty Terminated NCT00872547 Phase 4
49 Discontinuation of TNF-alpha Inhibitors in Spondylarthritis Patients With Low Disease Activity, and Re-initiation of Therapy if Disease Flares Terminated NCT00726804 Phase 4 Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity (etanercept or adalimumab)
50 REMission INDuction in Very Early Rheumatoid Arthritis Terminated NCT02935387 Phase 4

Search NIH Clinical Center for Rheumatic Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Angelica sinensis preparation
Antirheumatic Agent [EPC]
Cyclophosphamide
Hydrocortisone
hydrocortisone acetate
HYDROCORTISONE ACETATE PWDR
HYDROCORTISONE ACETONIDE
Hydrocortisone butyrate
hydrocortisone cypionate
hydrocortisone probutate
HYDROCORTISONE PWDR
Hydrocortisone sodium phosphate
Hydrocortisone sodium succinate
hydrocortisone valerate
HYDROCORTISONE,NONSTERILE PWDR
Hydroxychloroquine
Hydroxychloroquine Sulfate
leflunomide
Penicillamine
prednisolone
prednisolone acetate
PREDNISOLONE ACETATE PWDR
PREDNISOLONE PWDR
Prednisolone sodium phosphate
prednisolone tebutate
Prednisone
PREDNISONE PWDR
Triamcinolone
Triamcinolone Acetonide
TRIAMCINOLONE ACETONIDE PWDR
triamcinolone diacetate
triamcinolone hexacetonide

Genetic Tests for Rheumatic Disease

Anatomical Context for Rheumatic Disease

MalaCards organs/tissues related to Rheumatic Disease:

40
Heart, Testes, Bone, Skin, Lung, Tonsil, B Cells

Publications for Rheumatic Disease

Articles related to Rheumatic Disease:

(show top 50) (show all 15964)
# Title Authors PMID Year
1
The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. 54 61
19758114 2010
2
Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new "class effect" paradoxical phenomenon. Two case reports and literature review. 54 61
19147181 2010
3
The role of HMGB1 in the pathogenesis of rheumatic disease. 54 61
20123076 2010
4
Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases. 54 61
19423648 2009
5
Diagnostic and prognostic significance of serum C-reactive protein levels in patients admitted to the department of medicine. 54 61
19365169 2009
6
Use of the T-SPOT.TB assay to detect latent tuberculosis infection among rheumatic disease patients on immunosuppressive therapy. 54 61
19228655 2009
7
Repeated tuberculin skin testing following therapy with TNF-alpha inhibitors. 54 61
18795393 2009
8
Mycobacterial disease in patients with rheumatic disease. 54 61
19037226 2008
9
Erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus. 54 61
18709693 2008
10
The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. 54 61
18079191 2008
11
Prevalence of undiagnosed autoimmune rheumatic diseases in the first trimester of pregnancy. Results of a two-steps strategy using a self-administered questionnaire and autoantibody testing. 54 61
17970796 2008
12
High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease. 54 61
18598385 2008
13
What is the role for interleukin-1 receptor antagonist in rheumatic disease? 54 61
17369070 2007
14
Tumor necrosis factor-alpha inhibitor associated ulcerative colitis. 54 61
17496730 2007
15
Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists. 54 61
17300238 2007
16
When should we use TNF antagonists in children with rheumatic disease? 54 61
17174585 2007
17
Efficacy of the newest COX-2 selective inhibitors in rheumatic disease. 54 61
17691996 2007
18
Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients. 54 61
17014004 2006
19
Effectiveness of anakinra in rheumatic disease in patients naive to biological drugs or previously on TNF blocking drugs: an observational study. 54 61
16552464 2006
20
Structural, functional and immunologic characterization of folded subdomains in the Ro52 protein targeted in Sjögren's syndrome. 54 61
15916807 2006
21
Correlation of different bone markers with bone density in patients with rheumatic diseases on glucocorticoid therapy. 54 61
15887044 2006
22
Structural basis for recognition and sequestration of UUU(OH) 3' temini of nascent RNA polymerase III transcripts by La, a rheumatic disease autoantigen. 54 61
16387655 2006
23
Impact of selective cyclooxygenase-2 inhibitors on anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic disease. 54 61
15546461 2004
24
[The treatment of recurrent uveitis with TNF-alpha inhibitors]. 54 61
15470524 2004
25
Impact of selective cyclooxygenase-2 inhibitors on anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic disease. 54 61
15086694 2004
26
Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: the involvement of HLA-B27. 54 61
15006008 2004
27
Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. 54 61
14532145 2003
28
Mutations in the gene for familial Mediterranean fever: do they predispose to inflammation? 54 61
12966608 2003
29
Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection. 54 61
12847688 2003
30
Frequent infection with a viral pathogen, parvovirus B19, in rheumatic diseases of childhood. 54 61
12794831 2003
31
Pre-analytical problems in the measurement of tumor type pyruvate kinase (tumor M2-PK). 54 61
12820359 2003
32
Clinical application of tests used in rheumatology. 54 61
12450300 2002
33
Tumor necrosis factor-alpha blockade: a novel therapy for rheumatic disease. 54 61
12173297 2002
34
Serum levels of interleukin 15 in patients with rheumatic diseases. 54 61
11708407 2001
35
Interleukin-18: a novel cytokine in inflammatory rheumatic disease. 54 61
11465697 2001
36
Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. 54 61
11409666 2001
37
Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. 54 61
11302861 2001
38
Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. 54 61
11578019 2001
39
[Neopterin: new immunological marker of autoimmune rheumatic disease]. 54 61
11019525 2000
40
Referrals from general practice to an outpatient rheumatology clinic: disease spectrum and analysis of referral letters. 54 61
11147754 2000
41
Two yeast La motif-containing proteins are RNA-binding proteins that associate with polyribosomes. 54 61
10564276 1999
42
Relevance of tumour necrosis factor alpha gene polymorphism in rheumatic disease. 54 61
10461487 1999
43
Pathophysiological roles of calreticulin in autoimmune disease. 54 61
10320638 1999
44
Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. 54 61
9972954 1999
45
The cartilage collagens: a review of their structure, organization, and role in the pathogenesis of experimental arthritis in animals and in human rheumatic disease. 54 61
9535561 1998
46
Appropriate laboratory testing in rheumatic diseases. 54 61
9451199 1998
47
Soluble tumor necrosis factor receptor in serum of patients with arthritis. 54 61
9290265 1997
48
The C-reactive protein but not erythrocyte sedimentation rate is associated with clinical severity in patients with osteoarthritis of the knee or hip. 54 61
9263139 1997
49
Priming of NADPH oxidase by tumor necrosis factor alpha in patients with inflammatory and autoimmune rheumatic diseases. 54 61
8872505 1996
50
Cyclooxygenase 1 and 2 in rheumatic disease: implications for nonsteroidal anti-inflammatory drug therapy. 54 61
8870111 1996

Variations for Rheumatic Disease

Expression for Rheumatic Disease

Search GEO for disease gene expression data for Rheumatic Disease.

Pathways for Rheumatic Disease

Pathways related to Rheumatic Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14 TRIM21 TNFRSF11B TNF PTGS2 IL2RA IL1R1
2
Show member pathways
13.72 TNFRSF11B TNF PTGS2 PTGS1 IL2RA IL1R1
3
Show member pathways
13.33 TNF IL2RA IL1R1 IL1B IL11 IL10
4
Show member pathways
13.25 TNF IL2RA IL1R1 IL1B IFNG HMGB1
5
Show member pathways
12.88 TRIM21 TNFRSF11B TNF PTGS2 IL2RA IL1R1
6
Show member pathways
12.86 TNF IL2RA IL1B IFNG HLA-DRB1 HLA-B
7
Show member pathways
12.85 TNF IL2RA IL1B IL10 IFNG HLA-DRB1
8 12.82 TNF IL1B IFNG HLA-DRB1 HLA-B
9
Show member pathways
12.7 TNF IL1R1 IL1B IFNG CD40LG
10
Show member pathways
12.69 TNF IL2RA IL10 IFNG HLA-DRB1 CD40LG
11
Show member pathways
12.64 TNF IL1B IL10 IFNG CD40LG
12
Show member pathways
12.63 TNFRSF11B TNF IL1R1 IL1B CD40LG
13
Show member pathways
12.63 TNF IL2RA IL1R1 IL1B IL10 IFNG
14 12.4 TNF IL2RA IL1R1 HLA-DRB1 HLA-B
15
Show member pathways
12.38 IL2RA IL11 IL10 IFNG
16
Show member pathways
12.38 TNF PTGS2 PTGS1 IL1B IFNG CRP
17 12.37 TNF PTGS2 PTGS1 IL2RA IL1B IL10
18
Show member pathways
12.36 TNF PTGS2 IL1B IFNG
19
Show member pathways
12.36 TNF PTGS2 IL1R1 IL1B IFNG
20
Show member pathways
12.33 TNF IL2RA IL1B IL10 IFNG HLA-B
21 12.3 TNF IL1B IL10 IFNG HLA-DRB1
22
Show member pathways
12.26 TNF PTGS2 IL1R1 IL1B
23
Show member pathways
12.26 TNF IL1R1 IL1B IL11 IFNG
24
Show member pathways
12.25 TNF IL1B IFNG HMGB1
25
Show member pathways
12.25 TNF PTGS2 IL1B IL10
26 12.14 TNF IL1R1 IL1B IFNG
27
Show member pathways
12.14 TNF IL1R1 IL1B IL10 IFNG
28
Show member pathways
12.14 TNF PTGS2 IL1B IL10 IFNG HLA-DRB1
29 12.13 TNFRSF11B TNF IL1R1 IL1B IFNG
30
Show member pathways
12.09 TNF IL1B IFNG HMGB1
31 12.09 TNF PTGS2 IL1R1 IL1B IFNG
32 12.07 TNF IL2RA IL11 IL10 IFNG
33
Show member pathways
12.05 IL2RA IL1R1 IL1B IFNG HLA-DRB1
34 12.03 TNF PTGS2 IL1B IL10
35 11.99 TNF PTGS2 IL1R1 IL1B CD40LG
36 11.98 TNF IL1R1 IL1B IL10 IFNG
37 11.92 TNF IL1B IL11 IFNG HLA-DRB1
38 11.84 TNF IL2RA IL1R1 IL1B IL11 HLA-DRB1
39 11.82 TNF IL1B IL10 IFNG
40
Show member pathways
11.8 TNF PTGS2 IL2RA IFNG CD40LG
41 11.78 TNF IL1B IL10
42 11.74 TNF PTGS2 IL1B IL10 IFNG
43
Show member pathways
11.68 TNF IL2RA IFNG
44
Show member pathways
11.65 TNF PTGS2 IL1B IFNG CD40LG
45 11.58 TNFRSF11B TNF IL1B IFNG
46 11.57 TNF IL1B IFNG
47 11.56 TNF IL1B IFNG
48
Show member pathways
11.55 TNFRSF11B TNF IL1R1 IL1B
49 11.54 IL2RA IL10 IFNG
50 11.54 TNF IL2RA IL1R1 IL1B IL10 IFNG

GO Terms for Rheumatic Disease

Cellular components related to Rheumatic Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10 TNFRSF11B TNF IL1R1 IL1B IL11 IL10
2 extracellular space GO:0005615 9.7 TNFRSF11B TNF IL1B IL11 IL10 IFNG
3 external side of plasma membrane GO:0009897 9.63 TNF IL2RA IL1R1 HLA-DRB1 HLA-B CD40LG
4 cell surface GO:0009986 9.23 TNF IL2RA IL1R1 HMGB1 HLA-DRB1 HLA-B

Biological processes related to Rheumatic Disease according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 cellular response to lipopolysaccharide GO:0071222 9.94 TNF IL1B IL10 HMGB1
2 regulation of inflammatory response GO:0050727 9.87 TNF PTGS2 IL1R1
3 B cell differentiation GO:0030183 9.86 IL11 IL10 CD40LG
4 positive regulation of DNA-binding transcription factor activity GO:0051091 9.86 TRIM21 TNF IL1B IL10
5 regulation of insulin secretion GO:0050796 9.85 TNF IL1B IFNG
6 response to glucocorticoid GO:0051384 9.85 TNF PTGS2 IL10
7 positive regulation of T cell proliferation GO:0042102 9.84 IL2RA IL1B CD40LG
8 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.83 TNF IL1B HMGB1
9 positive regulation of interleukin-6 production GO:0032755 9.83 TNF IL1B HMGB1
10 positive regulation of autophagy GO:0010508 9.8 TRIM21 IFNG HMGB1
11 interferon-gamma-mediated signaling pathway GO:0060333 9.8 TRIM21 IFNG HLA-DRB1 HLA-B
12 positive regulation of phagocytosis GO:0050766 9.79 TNF IL1B IFNG
13 negative regulation of T cell proliferation GO:0042130 9.78 IL2RA IL10 HLA-DRB1
14 positive regulation of interferon-gamma production GO:0032729 9.77 TNF IL1R1 IL1B
15 positive regulation of interleukin-6 secretion GO:2000778 9.76 TNF IL1B HMGB1
16 negative regulation of interferon-gamma production GO:0032689 9.74 IL10 HMGB1 HLA-DRB1
17 positive regulation of interleukin-12 production GO:0032735 9.72 IFNG HMGB1 CD40LG
18 cytokine-mediated signaling pathway GO:0019221 9.7 TNF PTGS2 IL2RA IL1R1 IL1B IL11
19 cyclooxygenase pathway GO:0019371 9.69 PTGS2 PTGS1
20 astrocyte activation GO:0048143 9.69 TNF IL1B IFNG
21 negative regulation of amyloid-beta clearance GO:1900222 9.68 TNF IFNG
22 negative regulation of blood vessel diameter GO:0097756 9.68 PTGS2 CRP
23 positive regulation of MHC class II biosynthetic process GO:0045348 9.68 IL10 IFNG
24 negative regulation of lipid storage GO:0010888 9.68 TNF CRP
25 endothelial cell apoptotic process GO:0072577 9.67 TNF IL10
26 positive regulation of nitric oxide biosynthetic process GO:0045429 9.67 TNF PTGS2 IL1B IFNG
27 regulation of complement-dependent cytotoxicity GO:1903659 9.65 IL11 IL10
28 regulation of establishment of endothelial barrier GO:1903140 9.65 TNF IL1B
29 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.65 TNF IL1B IFNG
30 positive regulation of prostaglandin biosynthetic process GO:0031394 9.64 PTGS2 IL1B
31 negative regulation of cytokine secretion involved in immune response GO:0002740 9.63 TNF IL10
32 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.63 TNF IL1B IL10
33 positive regulation of T-helper 1 cell cytokine production GO:2000556 9.62 IL1R1 IL1B
34 regulation of immunoglobulin secretion GO:0051023 9.62 TNF CD40LG
35 inflammatory response to antigenic stimulus GO:0002437 9.61 IL2RA HMGB1 HLA-DRB1
36 immune response GO:0006955 9.61 TNF IL2RA IL1R1 IL1B IL10 IFNG
37 sequestering of triglyceride GO:0030730 9.59 TNF IL1B
38 receptor biosynthetic process GO:0032800 9.58 TNF IL10
39 positive regulation of chemokine biosynthetic process GO:0045080 9.58 TNF IL1B IFNG
40 positive regulation of vitamin D biosynthetic process GO:0060557 9.54 TNF IFNG
41 positive regulation of nitrogen compound metabolic process GO:0051173 9.52 TNF IFNG
42 positive regulation of fever generation GO:0031622 9.5 TNF PTGS2 IL1B
43 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.43 TNF IL1B IFNG
44 inflammatory response GO:0006954 9.28 TNF PTGS2 PTGS1 IL1R1 IL1B IL10

Molecular functions related to Rheumatic Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.11 TRIM21 TNFRSF11B TNF SSB RNPC3 PTGS2
2 cytokine activity GO:0005125 9.23 TNFRSF11B TNF IL1B IL11 IL10 IFNG
3 prostaglandin-endoperoxide synthase activity GO:0004666 8.96 PTGS2 PTGS1

Sources for Rheumatic Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....